Literature DB >> 11835523

Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy.

Kyouichi Tashiro1, Ichiro Koyanagi, Akemi Saitoh, Ayumi Shimizu, Toshihide Shike, Chizuru Ishiguro, Michiko Koizumi, Kazuhiko Funabiki, Satoshi Horikoshi, Isao Shirato, Yasuhiko Tomino.   

Abstract

We examined the correlation among the levels of urinary monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), hyperglycemia, and renal injuries in patients with type 2 diabetic nephropathy. The levels of urinary MCP-1, IL-8, protein excretion, blood urea nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) were measured in 24 patients with type 2 diabetic nephropathy and 14 healthy adults as controls. Diabetic nephropathy was classified into three stages: stage 1 = normoalbuminuric, stage 2 = microalbuminuric, and stage 3 = macroalbuminuric. All of the patients showed normal ranges in renal function tests. Levels of urinary MCP-1 in all patients with diabetic nephropathy were significantly higher than those in healthy adults (P < 0.05). The levels of urinary MCP-1 in patients with diabetic nephropathy increased gradually according to the clinical stage of this disease. In contrast, the levels of urinary IL-8 in patients with diabetic nephropathy increased in stages 2 and 3. There was a significant correlation between the levels of urinary IL-8 and those of HbA1c. High glucose may stimulate MCP-1 and/or IL-8 production and their excretion into the urine independently of the phases or pathological lesions of this disease. It appears that IL-8 increased in the early stage of diabetic nephropathy, and MCP-1 increased in the advanced stage of this disease. It was concluded that measurement of urinary MCP-1 and IL-8 may be useful for evaluating the degree of renal injuries in patients with type 2 diabetic nephropathy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835523      PMCID: PMC6807737          DOI: 10.1002/jcla.2057

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

1.  Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy.

Authors:  A Saitoh; Y Suzuki; M Takeda; K Kubota; K Itoh; Y Tomino
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

2.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.

Authors:  T Yoshimura; K Matsushima; S Tanaka; E A Robinson; E Appella; J J Oppenheim; E J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Monocyte chemoattractant protein-1 levels in patients with glomerular disease.

Authors:  B H Rovin; N Doe; L C Tan
Journal:  Am J Kidney Dis       Date:  1996-05       Impact factor: 8.860

4.  Cellular events in the evolution of experimental diabetic nephropathy.

Authors:  B A Young; R J Johnson; C E Alpers; E Eng; K Gordon; J Floege; W G Couser; K Seidel
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

5.  Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy.

Authors:  H Yokoyama; T Wada; K Furuichi; C Segawa; M Shimizu; K Kobayashi; S Su; N Mukaida; K Matsushima
Journal:  J Leukoc Biol       Date:  1998-04       Impact factor: 4.962

6.  Detection of urinary interleukin-8 in glomerular diseases.

Authors:  T Wada; H Yokoyama; N Tomosugi; Y Hisada; S Ohta; T Naito; K Kobayashi; N Mukaida; K Matsushima
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

7.  The role of macrophages in diabetic glomerulosclerosis.

Authors:  T Furuta; T Saito; T Ootaka; J Soma; K Obara; K Abe; K Yoshinaga
Journal:  Am J Kidney Dis       Date:  1993-05       Impact factor: 8.860

8.  Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis.

Authors:  R A Stahl; F Thaiss; M Disser; U Helmchen; K Hora; D Schlöndorff
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

9.  Regulation and production of IL-8 by human proximal tubular epithelial cells in vitro.

Authors:  J S Gerritsma; P S Hiemstra; A F Gerritsen; W Prodjosudjadi; C L Verweij; L A Van Es; M R Daha
Journal:  Clin Exp Immunol       Date:  1996-02       Impact factor: 4.330

10.  Cytokine-activated human mesangial cells generate the neutrophil chemoattractant, interleukin 8.

Authors:  Z Brown; R M Strieter; S W Chensue; M Ceska; I Lindley; G H Neild; S L Kunkel; J Westwick
Journal:  Kidney Int       Date:  1991-07       Impact factor: 10.612

View more
  40 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 3.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

4.  Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.

Authors:  Amira Shoukry; Shereen El-Arabi Bdeer; Rehab H El-Sokkary
Journal:  Mol Cell Biochem       Date:  2015-06-24       Impact factor: 3.396

5.  The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus.

Authors:  R Har; J W Scholey; D Daneman; F H Mahmud; R Dekker; V Lai; Y Elia; M L Fritzler; E B Sochett; H N Reich; D Z I Cherney
Journal:  Diabetologia       Date:  2013-02-15       Impact factor: 10.122

Review 6.  Effect of cilostazol in treating diabetes-associated microvascular complications.

Authors:  Nicole J Asal; Karolina A Wojciak
Journal:  Endocrine       Date:  2017-03-14       Impact factor: 3.633

Review 7.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier García-Pérez
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 8.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

9.  Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Authors:  Wen-Hao Tang; Fu-Huang Lin; Chien-Hsing Lee; Feng-Chih Kuo; Chang-Hsun Hsieh; Fone-Ching Hsiao; Yi-Jen Hung
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

10.  The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.

Authors:  David Z I Cherney; Heather N Reich; James W Scholey; Denis Daneman; Farid H Mahmud; Ronnie L H Har; Etienne B Sochett
Journal:  Diabetologia       Date:  2013-07-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.